Skip Navigation

Strengthen the Evidence for Maternal and Child Health Programs

Sign up for MCHalert eNewsletter

Search Results: MCHLine

Items in this list may be obtained from the sources cited. Contact information reflects the most current data about the source that has been provided to the MCH Digital Library.

Displaying records 1 through 4 (4 total).

Beachy SH, Johnson SG, Olson S, Berger AC, rapporteurs; Institute of Medicine, Roundtable on Translating Genomic-Based Research for Health. 2014. Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests: Workshop summary. Washington, DC: National Academies Press, 102 pp.

Annotation: This document summarizes a workshop held on February 27, 2013, in Washington, DC, to examine and discuss challenges and potential solutions for the co-development of targeted therapeutics and companion molecular tests for the prediction of drug response. Topics include perspectives from a variety of stakeholders including patients, providers, and laboratory representatives; pharmaceutical developers; and payers and regulators.

Contact: National Academies Press, 500 Fifth Street, N.W., Keck 360, Washington, DC 20001, Telephone: (202) 334-3313 Secondary Telephone: (888) 624-8373 Fax: (202) 334-2451 E-mail: [email protected] Web Site: http://www.nap.edu Available from the website. Document Number: ISBN 978-0-309-29821-6.

Keywords: Financing, Genomics, Laboratory techniques, Pharmaceutical research, Regulations, Testing, Therapeutics

Reyes C, Van de Putte L, Falcón AP, Levy RA. 2004. Genes, culture, and medicines: Bridging gaps in treatment for Hispanic Americans. Washington, DC: National Alliance for Hispanic Health, 32 pp.

Annotation: This report brings together a growing body of scientific research demonstrating substantial disparities in pharmaceutical therapy for Hispanic Americans. The report discusses disparities in relation to asthma and Hispanic children, mental illness, and status of research; genetics and individualized response to drugs in Hispanics in relation to asthma, diabetes, heart attack, and Alzheimers disease; clinical implications of variations in genes regulating drug metabolism; undertreatment of coexisting conditions; and communication, culture, and implications of optimal pharmaceutical care. Statistical information is presented in figures throughout the report. The report includes conclusions, recommendations, and references.

Contact: National Alliance for Hispanic Health, 1501 16th Street, N.W., Washington, DC 20036-1401, Telephone: (202) 387-5000 Secondary Telephone: (866) 783-2645 Fax: E-mail: Web Site: http://www.hispanichealth.org Available from the website.

Keywords: Alzheimers disease, Asthma, Children, Communication, Cultural factors, Culture, Diabetes, Drug therapy, Genetics, Heart diseases, Hispanic Americans, Mental disorders, Pharmaceuticals, Research, Treatment

Dijkstra H, Poot E, Wilczek I, eds. 1998. Biomedical research and orphan medicinal products: A roundtable conference organized by European Platform for Patients' Organisations, Science, and Industry, Brussels, 23 September 1997. [Brussels, Belgium]: European Platform for Patient's Organizations, Science and Industry, 122 pp.

Annotation: This book provide the texts of the presentations at a conference on biomedical research and orphan medicinal products. Section one addresses rare diseases. Section two discusses related research and development. Section three discusses legislation regarding orphan medicinal products. Section four discusses the related ethical aspects. And section five provides the related discussion of the conference.

Contact: European Platform for Patients' Organizations, Science and Industry, Square de Meeus-Rue de L'Industrie, 4, 1000 Brussels, Belgium Telephone: +32 2 503 13 07 Fax: +32 2 503 31 08 E-mail: [email protected] Web Site: http://www.epposi.org/ Available in libraries. Document Number: ISBN 90 261 1412 5.

Keywords: Conferences, Ethics, Europe, Legislation, Orphan drugs, Pharmaceuticals, Rare diseases, Research

National Institute of Allergy and Infectious Diseases, Task Force on Safer Childhood Vaccines. 1998. Task Force on Safer Childhood Vaccines: Final report and recommendations. [Bethesda, MD]: National Institute of Allergy and Infectious Diseases, 81 pp.

Annotation: This report summarizes the role of the Task Force on Safer Childhood Vaccines on the safe development of childhood vaccines, as mandated by law. Also, the report outlines the task force's recommendations on the improvement in licensing, manufacturing, processing, testing, labeling, warning, distributing, storing, administering, field surveillance, adverse reaction reporting, recalling of reactogenic lots or batches, and researching on vaccines. Report contents include vaccines as unique pharmaceuticals; current capabilities (and gaps) in assessing vaccine safety; and capabilities (and gaps) in promoting development and improvements in vaccine safety. The appendices include safety issues of recommended childhood vaccines; the impact of basic research and technological advances; new and emerging infectious diseases; laboratory evaluation of vaccine safety; evolving recommendations for the use of vaccines; assessing the causality of adverse medical events following vaccination – large linked databases, and a section of summary tables. A glossary and selected references are also provided.

Contact: HathiTrust Digital Library, University of Michigan, Telephone: (734) 764-8016 E-mail: [email protected] Web Site: https://www.hathitrust.org/digital_library Available from Hathitrust via participating libraries.

Keywords: Federal government, Immunization, Immunization programs, Pharmaceutical research, Regulations, Vaccination effects
   

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U02MC31613, MCH Advanced Education Policy, $3.5 M. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.